Encainide for treatment of atrioventricular reciprocating tachycardia in the Wolff-Parkinson-White syndrome.

[1]  E. Prystowsky,et al.  Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry. , 1987, American heart journal.

[2]  N. Fineberg,et al.  Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome. , 1986, The American journal of cardiology.

[3]  K. Kuck,et al.  Effect of encainide and flecainide on chronic ectopic atrial tachycardia. , 1986, Journal of the American College of Cardiology.

[4]  P. Brugada,et al.  Suppression of incessant supraventricular tachycardia by intravenous and oral encainide. , 1984, Journal of the American College of Cardiology.

[5]  P. Brugada,et al.  Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. , 1984, The American journal of cardiology.

[6]  K. Kuck,et al.  Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway. , 1984, The American journal of cardiology.

[7]  E. Prystowsky,et al.  Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome. , 1984, Circulation.

[8]  E. Prystowsky,et al.  Electrophysiology of oral encainide. , 1982, The American journal of cardiology.

[9]  F. Peters,et al.  Antiarrhythmic Efficacy of Encainide in Patients with Refractory Recurrent Ventricular Tachycardia , 1981, Circulation.